CRSP241213C48000
- 0.03
- -0.09-75.00%
CRISPR Therapeutics Newsroom
3 Things You Need to Know If You Buy CRISPR Therapeutics Today
Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers?
Chardan Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $94
Evercore Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $60
Crispr Therapeutics AG (CRSP) Gets a Hold From Evercore ISI
Analysts Are Bullish on Top Healthcare Stocks: Crispr Therapeutics AG (CRSP), Silence Therapeutics (SLN)
Chardan Capital Maintains Buy on CRISPR Therapeutics, Maintains $94 Price Target
CRISPR Therapeutics Analyst Ratings
William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Vertex Reports Positive Long-term Data for Casgevy
CRISPR Therapeutics Highlights CTX112 Data At ASH 2024, Showcasing Potential Clinical Benefits In R/R CD19-Positive B-Cell Malignancies; Receives FDA RMAT Designation For Follicular And Marginal Zone Lymphomas, With Phase 1 Trial Expanding Into...
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
CRISPR Therapeutics (CRSP) Upgraded to Buy: What Does It Mean for the Stock?
CMS Rolls Out New Payment Model for Vertex, Bluebird Gene Therapies
What CRISPR Therapeutics AG's (NASDAQ:CRSP) P/S Is Not Telling You
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Could Surge 58.3%: Read This Before Placing a Bet
Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investments
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?